APP and Alzheimer disease: Of note, replenishment of CPE expression by a non-invasive approach via the intranasal delivery of agomirs is sufficient to improve the behavioral and neurocognitive functions in APP/PS1 mice, making it particularly useful for clinical development into AD drugs.